AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients

 AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for CKD Patients With and Without Type-2 Diabetes

Shots:

  • The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19, but not on assisted ventilation. The studies are being conducted in the US and outside the US including the EU, Japan and South America
  • The drug demonstrated the clinical improvement in peer-reviewed case series of 19 hospitalized patients with COVID-19 and hypoxia and/or inflammation. Results were published in Science Immunology
  • Calquence is a BTK inhibitor, act by inhibiting its activity and has received the US FDA approval for hematological malignancies

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter

Related news: AstraZeneca Initiates CALAVI Study Evaluating Calquence (acalabrutinib) Against COVID-19

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post